Chromatographic isolation of cells and other complex biological materials
AssigneeJuno Therapeutics, Inc.
InventorHerbert Stadler
Life of this patent
Estimating the term…
Abstract
The present invention relates to the chromatographic isolation of a target cell or another complex biological material, in particular by column chromatography such as affinity chromatography or gel permeation chromatography. The invention employs a receptor binding reagent that binds to a receptor molecule that is located on the surface of a target cell. The invention in general provides novel methods for the traceless isolation of biologic materials such as cells, cell organelles, viruses and the like. The invention also relates to an apparatus for the isolation of cells and other complex biological materials.
Claims20
A chromatography column comprising an affinity chromatography stationary matrix suitable for a CD4+ lymphocyte cell separation,
- wherein the affinity chromatography stationary matrix comprises immobilized thereon both (1) an affinity reagent that comprises a streptavidin mutein and (2) a receptor binding reagent,
- wherein the streptavidin mutein is immobilized on the chromatography stationary matrix,
- wherein the receptor binding reagent comprises:
- (1) a Fab monomer fragment that binds CD4 on the surface of lymphocytes with (i) a dissociation constant (KD) of 10−3 to 10−7 M and/or (b) a dissociation rate constant (koff) of 3×10−5 sec−1 or greater, and (2) a binding partner C comprising a streptavidin-binding peptide fused to the C-terminus of the Fab monomer fragment,
- wherein the binding partner C of the receptor binding reagent is bound to a binding site Z of the immobilized streptavidin mutein of the affinity reagent, thereby immobilizing the receptor binding reagent on the chromatography matrix;
- wherein the Fab fragment comprises a heavy chain comprising the sequence set forth in SEQ ID NO:
- 1 and a light chain comprising the sequence set forth in SEQ ID NO:
- 2,
- wherein the streptavidin-binding peptide comprises the amino acid sequence of SEQ ID NO:
- 13 or SEQ ID NO:
- 3, and
- wherein the binding site Z has a lower dissociation constant (Kd) for biotin or a biotin analog than for the binding partner C.
Dependencies are inferred from the claim text.